These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11083637)

  • 1. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria.
    Sindelar G; Zhao X; Liew A; Dong Y; Lu T; Zhou J; Domagala J; Drlica K
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3337-43. PubMed ID: 11083637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus.
    Lu T; Zhao X; Li X; Drlica-Wagner A; Wang JY; Domagala J; Drlica K
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2703-9. PubMed ID: 11557458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering the specificity of antibacterial fluoroquinolones: benzenesulfonamide modifications at C-7 of ciprofloxacin change its primary target in Streptococcus pneumoniae from topoisomerase IV to gyrase.
    Alovero FL; Pan XS; Morris JE; Manzo RH; Fisher LM
    Antimicrob Agents Chemother; 2000 Feb; 44(2):320-5. PubMed ID: 10639357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.
    Zhou J; Dong Y; Zhao X; Lee S; Amin A; Ramaswamy S; Domagala J; Musser JM; Drlica K
    J Infect Dis; 2000 Aug; 182(2):517-25. PubMed ID: 10915083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa.
    Kitamura A; Hoshino K; Kimura Y; Hayakawa I; Sato K
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1467-71. PubMed ID: 7492087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
    Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
    Lu T; Zhao X; Drlica K
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2969-74. PubMed ID: 10582891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.
    Heaton VJ; Ambler JE; Fisher LM
    Antimicrob Agents Chemother; 2000 Nov; 44(11):3112-7. PubMed ID: 11036032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.
    Smith HJ; Walters M; Hisanaga T; Zhanel GG; Hoban DJ
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3954-8. PubMed ID: 15388458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis.
    Malik M; Marks KR; Mustaev A; Zhao X; Chavda K; Kerns RJ; Drlica K
    Antimicrob Agents Chemother; 2011 May; 55(5):2335-43. PubMed ID: 21383100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.
    Fukuda H; Kishii R; Takei M; Hosaka M
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1649-53. PubMed ID: 11353607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.
    Yague G; Morris JE; Pan XS; Gould KA; Fisher LM
    Antimicrob Agents Chemother; 2002 Feb; 46(2):413-9. PubMed ID: 11796351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification and inhibition by quinolones of DNA gyrases from Mycobacterium avium, Mycobacterium smegmatis and Mycobacterium fortuitum bv. peregrinum.
    Guillemin I; Sougakoff W; Cambau E; Revel-Viravau V; Moreau N; Jarlier V
    Microbiology (Reading); 1999 Sep; 145 ( Pt 9)():2527-2532. PubMed ID: 10517605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
    Zhao X; Xu C; Domagala J; Drlica K
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones.
    Revel V; Cambau E; Jarlier V; Sougakoff W
    Antimicrob Agents Chemother; 1994 Sep; 38(9):1991-6. PubMed ID: 7811008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of a gyrA plasmid for genetic characterization of fluoroquinolone-resistant Staphylococcus aureus.
    Tankovic J; Duval J; Courvalin P
    FEMS Immunol Med Microbiol; 1994 Jun; 9(1):35-9. PubMed ID: 7920462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.